1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Express Scripts Holding Company

Express Scripts Holding Company

ESRX
Express Scripts Holding CompanyUS flagNASDAQ
92.33
USD
- -
- -
Express Scripts Holding Company
ESRX
(NASDAQ)

Recent

price

92.33

P/E

ratio

- -

div

yld

- -

ROIC.AI

2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
TTM
FRC
19.68
21.35
24.74
27.66
31.58
35.09
44.15
46.96
83.52
92.09
128.34
128.74
134.46
147.68
159.97
172.5
179.98
Revenue per Share
0.33
0.4
0.46
0.68
0.85
1.09
1.56
1.57
2.19
2.55
1.8
2.28
2.68
3.59
5.43
7.79
8.7
Basic EPS, GAAP
0.59
0.65
0.73
1.25
1.06
1.44
2.04
3.08
3.71
4.09
6.32
5.36
5.48
6.61
7.32
9.22
7.74
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.99
1.39
1.87
2.63
3.61
4.97
6.76
7.95
9.98
13.28
2.84
4.85
7.9
12.2
18.84
28.15
33.56
Book Value per Share
-1.01
-0.74
-1.24
-2.62
-3.47
-4.49
-4.29
-7.31
-6.69
-9.25
-30.09
-26.56
-28.62
-32.46
-34.57
-38.96
-33.67
Tangible Book Value per Share
623
623
611
588
559
521
498
527
538
501
731
809
750
689
627
580
563
Basic Weighted Avg Shares
12,261
13,295
15,115
16,266
17,660
18,274
21,978
24,749
44,973
46,128
93,858
104,099
100,887
101,752
100,288
100,065
101,353
Sales/Revenue/Turnover
3.03
3.38
3.26
3.95
4.67
5.81
5.83
6.05
4.6
5.01
2.97
3.41
3.57
4.26
5.07
5.49
5.27
Operating Margin (%)
92
62
82
95
101
98
98
110
245
253
1,873
2,447
2,243
2,359
2,155
1,802
1,958
Depreciation Expense
203
250
278
400
474
568
776
828
1,181
1,276
1,313
1,845
2,008
2,476
3,404
4,517
4,900
Net Income, GAAP
38.16
38.16
38.26
34.96
35.94
36.45
35.76
36.87
36.89
36.98
38.03
36.43
33.63
35.31
22.58
8.06
68.95
Effective Tax Rate (%)
1.65
1.88
1.84
2.46
2.69
3.11
3.53
3.34
2.63
2.77
1.4
1.77
1.99
2.43
3.39
4.51
4.83
Profit Margin (%)
-150
-66
-370
-137
-657
-507
-678
-1,313
-976
2,600
-2,300
-4,744
-6,449
-5,096
-4,065
-5,889
-4,339
Working Capital
563
455
412
1,401
1,270
1,760
1,340
2,492
2,494
7,076
14,980
12,363
11,013
13,946
14,846
14,982
12,974
LT Debt
1,003
1,194
1,196
1,465
1,125
696
1,078
3,552
3,607
2,474
23,396
21,845
20,064
17,380
16,244
18,125
20,573
Total Equity
16.74
17.26
18.56
18.16
19.02
25.48
29.61
18.5
19.38
17.5
6.92
6.01
6.89
8.43
12.16
15.32
- -
Return on Invested Capital (%)
20.9
19.95
19.2
17.26
14.54
14.06
16.97
14.45
16.19
12.96
10.26
12.24
12.66
12.76
15.25
16.95
46.55
Return on Capital (%)
39.44
33.7
27.7
29.76
26.62
24.65
26.08
21.9
24.69
21.21
30.08
61.51
40.76
34.55
33.68
32.11
29.79
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'18
Jun'18
Sep'18
ST Debt
86
1,533
2,021
LT Borrowings
14,900
13,458
12,974
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
562
562
564
Market Capitalization
39,419
43,653
53,505

Working Capital

FRC

•

in mil. unless spec.
Mar'18
Jun'18
Sep'18
Total Current Assets
11,475
13,170
14,352
Cash, Cash Equivalents & STI
2,318
2,942
3,706
Accounts Receivable, Net
6,794
4,105
4,070
Inventories
2,028
2,293
2,169
Total Current Liabilities
16,723
18,587
18,691
Payables & Accruals
16,638
17,054
16,670
ST Debt
86
1,533
2,021
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
107.7%
-4.62%
11.58%
Free Cash Flow
26.28%
3.36%
16.61%
Net Income, GAAP
23.98%
28.57%
32.69%
Sales/Revenue/Turnover
22.77%
1.4%
-0.22%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
24,792
25,222
25,410
24,863
100,288
2017
24,655
25,348
24,683
25,379
100,065
2018
24,769
25,642
25,563
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
0.82
1.14
1.16
2.36
5.43
2017
0.91
1.38
1.47
4.12
7.79
2018
1.11
1.56
1.9
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -
Similar Companies
Ohki Healthcare Holdings Co.,Ltd. (3417.T)
Easywell Biomedicals, Inc. (1799.TWO)
Smruthi Organics Limited (SMRUTHIORG.BO)
Unity Biotechnology, Inc. (0YC0.L)
China De Xiao Quan Care Group Co., Ltd (CDXQ)
Panion & Bf Biotech Inc. (1760.TW)
Business
Express Scripts Holding Company, a subsidiary of The Cigna Group since its $67 billion acquisition in December 2018, provides pharmacy benefit management services to health plans, employers, government programs and other clients in the United States. The company offers network-pharmacy claims processing; home delivery pharmacy through Express Scripts Pharmacy; specialty pharmacy services via Accredo; benefit-design consultation; drug utilization review and formulary management; medical and drug data analysis; and related solutions including SafeGuardRx programs for high-cost categories such as oncology, inflammatory conditions, diabetes and hepatitis. It operates a national network of over 65,000 retail pharmacies, serves major clients including the U.S. Department of Defense's Tricare program and Centene Corporation, and maintains headquarters in St. Louis, Missouri, where it was founded in 1986. Recent developments include a multi-year strategic partnership with Centene effective January 2024 to manage pharmacy benefits for approximately 20 million members; a collaboration with CPESN USA announced in 2024 to enhance care coordination for Medicare beneficiaries with hypertension and diabetes while expanding access to independent pharmacies; the launch of Express Scripts ClearNetwork in early 2024 offering clients a transparent cost-plus pricing model for brand, generic and specialty drugs using benchmarks like Predictive Acquisition Cost; and a transition announced in October 2025 to a point-of-sale rebate model for commercial clients that passes negotiated savings directly to members at the pharmacy counter, eliminating post-sale rebates and projecting average 30% savings on brand-name medications.

Company News

Company News APIChatGPT

  • nypost.com

    UnitedHealth, CVS Caremark, Express Scripts sued by FTC over skyrocketing insulin prices